乳腺癌新辅助化疗对ER、PR、Her-2 表达的影响

Effect of neoadjuvant chemotherapy for breast cancer on the expression of ER, PR and Her-2

摘要:

乳腺癌是目前女性恶性肿瘤中发病率最高的恶性肿瘤，且发病率呈逐年递增趋势，新辅助化疗 具有降低乳腺癌患者术前临床分期，缩小原发灶范围，控制远端转移及体内药敏试验的作用，同时为术后辅助 治疗提供指导。乳腺癌同时也是一种激素依赖性恶性肿瘤，临床上通常通过检测乳腺癌组织中的雌激素受体 （ER）、孕激素受体（PR）及人表皮生长因子受体-2（Her-2）来制订术前新辅助化疗的方案及术后是否需 要内分泌或靶向治疗。由于术后的内分泌及靶向治疗主要取决于以上标志物的表达水平，所以在新辅助化疗 作用于残余癌组织中，这些肿瘤标志物的表达是否一致还存在争议，这些标志物表达的变化对于后续治疗方 案的影响尚无定论。该文通过检索阅读相关文献，总结归纳了乳腺癌新辅助化疗对ER、PR 及Her-2 表达的 影响。

Abstract:

Breast cancer is the most common malignant tumor in female malignant tumors, and the incidence rate is increasing year by year. For advanced breast cancer patients, neoadjuvant chemotherapy can reduce preoperative clinical stage, reduce the scope of primary tumor, control distal metastasis and in vivo. The role of drug susceptibility testing, while providing guidance for postoperative adjuvant therapy. Breast cancer is also a hormonedependent malignant tumor. Clinically, it is commonly used to detect estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (Her-2) in breast cancer tissues. To determine the preoperative neoadjuvant chemotherapy regimen and whether endocrine or targeted therapy is needed after surgery. Since postoperative internal therapy and targeted therapy mainly depend on the expression status of the above markers, it is still controversial whether the expression of these tumor markers is consistent in neoadjuvant chemotherapy for residual cancer tissues. The impact of changes on subsequent treatment options remains conclusive. This article summarizes the effects of neoadjuvant chemotherapy on the expression of ER, PR and Her-2 in breast cancer by searching and reading related literature.